Industry News

Daiichi Sankyo and Kitasato Pharma to terminate sales agreement of Influenza HA vaccine

  • Posted on: 28 March 2020
  • By: admin

Daiichi Sankyo Company, Limited and Kitasato Pharmaceutical Industry Co., Ltd. (hereinafter, “ Kitasato Pharmaceutical Industry”) announced the termination of their cooperative sales agreement for Influenza HA Vaccine “Daiichi Sankyo” 1 mL and Influenza HA Vaccine Syringe “Daiichi Sankyo” 0.25 mL and 0.5 mL on March 31, 2020 in Japan.

AstraZeneca collaborate with Silence Therapeutics to discover, develop and commercialise small siRNA

  • Posted on: 27 March 2020
  • By: admin

AstraZeneca will collaborate with Silence Therapeutics to discover, develop and commercialise small interfering RNA (siRNA) therapeutics for the treatment of Cardiovascular, Renal, Metabolic and Respiratory diseases.

Novartis, Teva and Mylan to supply around 200 millions of doses of antimalarial drugs to fight against corona virus

  • Posted on: 21 March 2020
  • By: PharmaTutor News

Hydroxychloroquine and a related drug, chloroquine, are currently under evaluation in clinical trials for the treatment of COVID-19. Also, there are few results suggested that Hydroxychloroquine is effective against COVID-19. Three pharma giants Novartis, Mylan and Teva Pharma announced that they will donate millions of doses of hydroxychloroquine to support the global COVID-19 pandemic response.

Zydus announces world’s first drug for the treatment of Non-Cirrhotic NASH

  • Posted on: 5 March 2020
  • By: PharmaTutor News

Zydus Cadila, an innovation-driven global pharmaceutical company announced that the Drug Controller General of India (DCGI) has approved its New Drug Application (NDA) for Saroglitazar for the treatment of Non-Cirrhotic Non-Alcoholic SteatoHepatitis (NASH) in India.

Indian Government restricted export of Paracetamol and other medication due to COVID-19 outbreak

  • Posted on: 4 March 2020
  • By: PharmaTutor News

The Government has made amendments in the export policy and restricted export of specified APIs (Active Pharmaceutical Ingredients) and formulations made from 13 APIs for safety purpose due to COVID-19 outbreak in India. A notification issued by Directorate General of Foreign Trade, Commerce and Industry says that the restrictions will come into immediate effect and until further orders.